Antimicrobial Stewardship in Chronic Wound Care

A clinician prescribes a course of oral antibiotics for a diabetic foot ulcer that has been stalled for six weeks. The wound does not improve. A second course follows. The patient completes both rounds but the wound is unchanged, and now the culture returns with a resistant organism. Antibiotic days have accumulated, but wound closure has not advanced.

This sequence is not an outlier. It is a pattern driven by biofilm — and antimicrobial stewardship in wound care must address biofilm directly, not just the downstream antibiotic prescriptions that biofilm makes futile.

The Antimicrobial Burden in Chronic Wound Care

In the United States, more than 2.8 million antimicrobial-resistant infections occur each year and more than 35,000 people die as a result. When Clostridioides difficile — a pathogen strongly associated with antibiotic exposure — is included, the toll exceeds 3 million infections and 48,000 deaths annually (CDC, 2019 AR Threats Report).

Wound care contributes meaningfully. A 2026 analysis of 45.1 million outpatient cutaneous wound visits found that antimicrobials represented 13.1% of medications prescribed — 14.9% in acute wound visits, 10.2% in chronic (Grada et al., 2026). Cephalexin alone accounted for 32.1%. Chronic wound visits showed a heterogeneous antimicrobial profile spanning topical mupirocin, cephalexin, trimethoprim-sulfamethoxazole, and topical nystatin — a pattern the authors characterized as an "opportunity to strengthen antimicrobial stewardship."

The paradox is well-documented: systemic antibiotics prescribed for infected chronic wounds often fail because the organisms are biofilm-protected. Metagenomic analysis consistently identifies resistance genes spanning β-lactams, aminoglycosides, fluoroquinolones, tetracyclines, and macrolides in chronic wound communities (Sadia et al., 2026). Against biofilm-protected polymicrobial communities, standard antibiotics produce selection pressure without clinical clearance.

Biofilm Disruption: Where Biologics Enter the Stewardship Equation

The mechanism by which biologic allografts contribute to antimicrobial stewardship is indirect but clinically relevant. Biologic scaffolds — including amniotic membrane allografts and placental-derived extracellular matrix products — do not contain antibiotics. Their contribution to stewardship comes through two pathways: biofilm suppression through wound bed optimization, and delivery of endogenous antimicrobial peptides.

Biologic allografts provide an extracellular matrix scaffold that supports granulation, delivers growth factors, and modulates inflammation. Applied to a properly debrided wound bed, the scaffold promotes epithelialization and closure. A closing wound is inhospitable to biofilm reformation. The antimicrobial effect is structural and biologic, not pharmacologic.

A second mechanism involves antimicrobial peptides (AMPs) endogenous to amniotic membrane — defensins, cathelicidins, and other host-defense peptides active against Gram-positive and Gram-negative organisms. These peptides physically compromise bacterial membranes through mechanisms distinct from conventional antibiotics, reducing the probability of resistance evolution via single-point mutations. While peptide concentration in a processed allograft is lower than in a dedicated AMP dressing, the background antimicrobial environment may reduce early post-application recolonization.

Antimicrobial Peptide Dressings as Targeted Adjuncts

Antimicrobial peptide-based dressings represent a parallel pathway: non-antibiotic topical antimicrobials that complement biologic grafts within a stewardship framework. Unlike silver, iodine, or PHMB — which reduce bacterial burden but may be cytotoxic at sustained concentrations — AMP dressings target bacterial membranes with lower mammalian cytotoxicity.

Nitric oxide-releasing gels (NORGs) combine multi-target bactericidal activity via oxidative and nitrosative stress with pro-healing effects including angiogenesis, inflammation modulation, and improved microvascular perfusion (Teskey et al., 2026). The mechanism sidesteps conventional resistance pathways; preclinical models demonstrate activity against multidrug-resistant organisms with a low resistance-induction profile.

AMP dressings and NORGs are best positioned as the bridge between debridement and biologic application: debridement removes bulk biofilm, the antimicrobial dressing suppresses planktonic and early biofilm bacteria, and the allograft is applied to a cleaner bed. None of these steps replaces systemic antibiotics when signs of spreading infection are present.

Clinical Evidence on Reduced Antibiotic Days

Direct evidence linking biologic allograft use to reduced systemic antibiotic days is limited. Most published studies report wound closure rates and cost per closed wound — not antibiotic days avoided. This is a recognized evidence gap.

What the existing evidence supports is the mechanistic pathway: repeated debridement removes biofilm, non-antibiotic topical agents suppress recolonization, and biologic scaffolds accelerate closure. A wound that closes in 8 weeks instead of 20 weeks receives fewer total weeks of antimicrobial exposure. The antibiotic-sparing effect follows from accelerated closure — it is not an independent pharmacologic property of the graft.

Clinicians should document antibiotic days in conjunction with biologic applications. Standardized stewardship metrics — antimicrobial start dates, stop dates, indications, and culture results — belong in the wound care record alongside wound measurements and graft application dates.

A Stewardship-Oriented Decision Framework

The CDC Core Elements of Hospital Antibiotic Stewardship Programs emphasize accountability, drug expertise, action, tracking, reporting, and education. These principles translate directly to chronic wound care. A stewardship-oriented wound care protocol should include the following decision points.

Step 1: Is a systemic antibiotic indicated? Systemic antibiotics are appropriate for spreading infection, cellulitis, osteomyelitis, or systemic signs of infection. They are not indicated for colonized biofilm in the absence of spreading infection.

Step 2: Have you identified the organism and susceptibilities? Tissue biopsy or curettage is preferred over surface swabs for biofilm-protected wounds. Culture-directed therapy reduces unnecessary broad-spectrum exposure.

Step 3: Is the wound bed prepared? Sharp debridement remains the cornerstone of biofilm management. Re-debride if slough or biofilm recurs. Do not place an expensive biologic allograft on a biofilm-heavy wound bed.

Step 4: Does the wound need topical antimicrobial suppression? Non-antibiotic options — silver, cadexomer iodine, PHMB, AMP dressings, NORGs — should be considered before or in place of topical antibiotics. Topical antibiotics contribute to resistance without necessarily improving outcomes.

Step 5: Is the wound ready for a biologic scaffold? When the wound bed is clean, granular, and free of active infection, biologic allografts may accelerate closure through growth factor delivery and ECM scaffolding. The antibiotic-sparing effect is mediated through faster closure, not through a direct antimicrobial mechanism.

Step 6: Reassess at each visit. If clinical signs of infection recur, return to Step 1. Do not extend the same antibiotic regimen into a second month without re-culturing and re-evaluating.

Antimicrobial Stewardship Requires Multidisciplinary Coordination

Antimicrobial stewardship in chronic wound care is not the sole responsibility of the wound clinician. It requires coordination between wound care teams, infectious disease specialists, antimicrobial stewardship committees, and hospital pharmacists. An outpatient wound clinic that lacks access to an ID pharmacist for stewardship consultation should establish a referral pathway. A hospital wound care service that does not include wound patients in the facility's antimicrobial stewardship dashboard is missing a substantial opportunity for intervention.

The CDC identifies tracking and reporting as core stewardship elements. Wound care services should track the proportion of patients on systemic antibiotics, the average antibiotic days per wound episode, and the frequency of culture-directed vs. empiric therapy. These metrics belong in facility-level stewardship reports alongside surgical prophylaxis compliance and ICU antibiotic utilization data.

Biologic allografts and antimicrobial peptide dressings are not antibiotic replacements. They do not treat systemic infection, they do not replace debridement, and they are not indicated for wounds with active, spreading infection. They are adjunctive tools within a stewardship protocol — tools that may reduce the circumstances in which systemic antibiotics are prescribed, the duration for which they are needed, and the frequency with which they fail.

The goal of antimicrobial stewardship in wound care is not to eliminate antibiotics. It is to use them when they are needed, stop them when they are not, and deploy every available tool — mechanical, biologic, and topical — to reduce the total antibiotic burden a wound patient carries from presentation to closure.

References

1. Centers for Disease Control and Prevention. Antibiotic Resistance Threats in the United States, 2019. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2019. Available at: https://www.cdc.gov/antimicrobial-resistance/data-research/threats/
2. Centers for Disease Control and Prevention. Core Elements of Hospital Antibiotic Stewardship Programs. Atlanta, GA: CDC; 2019. Available at: https://www.cdc.gov/antibiotic-use/core-elements/hospital.html
3. Grada A, Chandy RJ, Park J, Feldman SR. Outpatient Cutaneous Wound Care in the United States: Specialty Distribution and Antimicrobial Prescribing Patterns. Antibiotics (Basel). 2026;15(2):142. PMID: 41750440.
4. Teskey SJL, Khoma L, Lorbes M, Miller CC. Nitric Oxide-Releasing Gels in the Context of Antimicrobial Stewardship, Biofilm Management, and Wound-Repair Biology. Antibiotics (Basel). 2026;15(1):54. PMID: 41594093.
5. Sadia H, Amin A, Khalid N, Ahmed I. Antimicrobial resistance and virulence in polymicrobial chronic wound infections: A metagenomic perspective. J Infect Public Health. 2026;19(8):103280. PMID: 42247807.
6. Schultz G, Bjarnsholt T, Dubertret T, et al. Consensus guidelines for the identification and treatment of biofilms in chronic nonhealing wounds. Wound Repair Regen. 2017;25(5):744-757.
7. International Wound Infection Institute. Wound infection in clinical practice: IWII consensus document. 2023 Update. Wounds International.
8. Infectious Diseases Society of America. IDSA Antimicrobial Stewardship Guidelines. Available at: https://www.idsociety.org/practice-guideline/antimicrobial-stewardship/

Disclaimer

This article is for educational purposes and does not constitute medical advice. Biologic allografts and antimicrobial peptide dressings are adjunctive to standard wound care and antimicrobial stewardship protocols. They do not replace systemic antibiotics when indicated for spreading infection, cellulitis, osteomyelitis, or systemic involvement. Treatment decisions should follow manufacturer Instructions for Use, institutional protocols, and current antimicrobial stewardship guidelines. Antimicrobial stewardship requires multidisciplinary coordination.